QURE
Price
$14.25
Change
-$0.14 (-0.97%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
778.17M
19 days until earnings call
TRVI
Price
$6.34
Change
+$0.07 (+1.12%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
586.86M
14 days until earnings call
Ad is loading...

QURE vs TRVI

Header iconQURE vs TRVI Comparison
Open Charts QURE vs TRVIBanner chart's image
uniQure
Price$14.25
Change-$0.14 (-0.97%)
Volume$15.36K
Capitalization778.17M
Trevi Therapeutics
Price$6.34
Change+$0.07 (+1.12%)
Volume$13.66K
Capitalization586.86M
QURE vs TRVI Comparison Chart
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. TRVI commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Buy and TRVI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (QURE: $14.39 vs. TRVI: $6.27)
Brand notoriety: QURE and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 98% vs. TRVI: 44%
Market capitalization -- QURE: $778.17M vs. TRVI: $586.86M
QURE [@Biotechnology] is valued at $778.17M. TRVI’s [@Biotechnology] market capitalization is $586.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, TRVI is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 4 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • QURE’s TA Score: 4 bullish, 5 bearish.
  • TRVI’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, QURE is a better buy in the short-term than TRVI.

Price Growth

QURE (@Biotechnology) experienced а +53.25% price change this week, while TRVI (@Biotechnology) price change was +2.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

QURE is expected to report earnings on Jul 31, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($778M) has a higher market cap than TRVI($587M). TRVI YTD gains are higher at: 52.184 vs. QURE (-18.516). TRVI has higher annual earnings (EBITDA): -44.19M vs. QURE (-160.74M). QURE has more cash in the bank: 368M vs. TRVI (65.5M). TRVI has less debt than QURE: TRVI (1.11M) vs QURE (66.1M). QURE has higher revenues than TRVI: QURE (27.1M) vs TRVI (0).
QURETRVIQURE / TRVI
Capitalization778M587M133%
EBITDA-160.74M-44.19M364%
Gain YTD-18.51652.184-35%
P/E RatioN/AN/A-
Revenue27.1M0-
Total Cash368M65.5M562%
Total Debt66.1M1.11M5,939%
FUNDAMENTALS RATINGS
QURE vs TRVI: Fundamental Ratings
QURE
TRVI
OUTLOOK RATING
1..100
2566
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
10055
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
3536
P/E GROWTH RATING
1..100
88100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (58) in the Pharmaceuticals Major industry is in the same range as QURE (74) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

TRVI's Profit vs Risk Rating (55) in the Pharmaceuticals Major industry is somewhat better than the same rating for QURE (100) in the Biotechnology industry. This means that TRVI’s stock grew somewhat faster than QURE’s over the last 12 months.

TRVI's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as QURE (98) in the Biotechnology industry. This means that TRVI’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (35) in the Biotechnology industry is in the same range as TRVI (36) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to TRVI’s over the last 12 months.

QURE's P/E Growth Rating (88) in the Biotechnology industry is in the same range as TRVI (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QURETRVI
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 17 days ago
86%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRIEX12.69N/A
N/A
Meridian Hedged Equity Investor
FHJUX38.97N/A
N/A
Fidelity Advisor Europe A
TRZRX14.43N/A
N/A
T. Rowe Price Real Assets Z
SGACX17.89N/A
N/A
Virtus SGA Global Growth C
CSGYX24.37N/A
N/A
Columbia Small Cap Growth Inst3

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with CMRX. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then CMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
N/A
CMRX - QURE
52%
Loosely correlated
N/A
NAMS - QURE
52%
Loosely correlated
+2.86%
HOOK - QURE
44%
Loosely correlated
+4.00%
AXON - QURE
42%
Loosely correlated
+3.82%
ABSI - QURE
38%
Loosely correlated
-0.47%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+3.29%
PTGX - TRVI
43%
Loosely correlated
+0.72%
CKPT - TRVI
34%
Loosely correlated
N/A
MLYS - TRVI
31%
Poorly correlated
+2.42%
AURA - TRVI
31%
Poorly correlated
+0.88%
QURE - TRVI
30%
Poorly correlated
N/A
More